{"id":1898,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2019-09-13","marketCap":1971.23,"name":"SpringWorks Therapeutics Inc","phone":"12038839490.0","outstanding":62.58,"symbol":"SWTX","website":"https://www.springworkstx.com/","industry":"Biotechnology"},"price":33.6825,"year":2023,"month":12,"day":14,"weekday":"Thursday","title":"Recent News and Events Impacting SpringWorks Therapeutics Inc Stock","date":"2023-12-14","url":"/posts/2023/12/14/SWTX","content":[{"section":"FDA Approval of Nirogacestat","text":"One significant development for SpringWorks Therapeutics Inc was the FDA approval of their drug candidate, nirogacestat, for the treatment of adult patients with desmoid tumors. This approval has the potential to positively impact the company's stock performance as it allows them to commercialize the drug and generate revenue from sales."},{"section":"Collaboration with GlaxoSmithKline","text":"SpringWorks Therapeutics Inc entered into a collaboration agreement with GlaxoSmithKline (GSK) to develop and commercialize therapies for rare genetic diseases. This partnership has the potential to bring in substantial funding and expertise for SpringWorks, which could positively impact their stock performance."},{"section":"Positive Clinical Trial Results","text":"The company announced positive results from a Phase 2b clinical trial evaluating their investigational drug, mirdametinib, in patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). These results demonstrated meaningful clinical activity and a favorable safety profile, suggesting the potential for future regulatory approvals and commercial success. Such positive trial results can boost investor confidence and drive stock performance."},{"section":"Expansion of Pipeline","text":"SpringWorks Therapeutics Inc recently expanded their pipeline by acquiring exclusive worldwide rights to develop and commercialize a preclinical-stage gamma secretase inhibitor program from Pfizer. This addition to their portfolio enhances the company's potential to develop innovative treatments for various diseases, potentially attracting investor interest and positively impacting stock performance."},{"section":"Conference Presentations","text":"SpringWorks Therapeutics Inc participated in several conferences and presented data on their pipeline programs, including nirogacestat and mirdametinib. These presentations showcase the company's progress and reinforce investor confidence in their ability to drive clinical advancements and commercial success, potentially influencing stock performance."},{"section":"Market Volatility and Investor Sentiment","text":"Like any pharmaceutical company, SpringWorks Therapeutics Inc is also susceptible to external factors such as market volatility and investor sentiment. Macroeconomic conditions, changes in regulations, and the overall market outlook can impact investor confidence and subsequently affect stock performance."},{"section":"Competitor Developments","text":"The actions and advancements of competitors in the biopharmaceutical industry can also have an influence on SpringWorks Therapeutics Inc's stock performance. Positive developments or breakthrough advancements by competitors may lead to increased competition, potentially impacting investor perception and stock performance."},{"section":"Clinical Trial Setbacks","text":"Although SpringWorks Therapeutics Inc has recently reported positive clinical trial results, setbacks or failures in future trials could have a negative impact on their stock performance. Clinical trial outcomes can significantly affect investor confidence and the perceived value of the company's pipeline."}],"tags":["CrossOver55","Long","Biotechnology"],"news":[{"category":"company","date":1702069500,"headline":"SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares","id":124406138,"image":"https://media.zenfs.com/en/globenewswire.com/1d76a773b101d90fe2cf67cbb32c7cff","symbol":"SWTX","publisher":"Yahoo","summary":"STAMFORD, Conn., Dec. 08, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the closing of its previously announced underwritten public offering of 10,905,171 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,422,413 shares of common stock in","url":"https://finance.yahoo.com/news/springworks-therapeutics-announces-closing-upsized-210500925.html"},{"category":"company","date":1702060200,"headline":"Bumble, Peabody Energy, and More Stocks See Action From Activist Investors","id":124404832,"image":"https://images.barrons.com/im-80858317/social","symbol":"SWTX","publisher":"MarketWatch","summary":"Hedge fund firm Elliott Management sold nearly 3.2 million shares of coal company Peabody Energy to trim its stake to 13.7%.","url":"https://www.marketwatch.com/articles/bumble-peabody-energy-and-more-stocks-see-action-from-activist-investors-c04904f1"},{"category":"company","date":1702030740,"headline":"Goldman Sachs pharmaceuticals analysts hold an analyst/industry conference call","id":124415142,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3247970048"},{"category":"company","date":1702005180,"headline":"SpringWorks Therapeutics announces closing of upsized public offering of common stock","id":124415143,"image":"","symbol":"SWTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3248346997"},{"category":"company","date":1702003620,"headline":"Buy Rating Justified: Springworks Therapeutics’s Ogsiveo Poised to Transform Desmoid Tumor Treatment","id":124415144,"image":"","symbol":"SWTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3248314001"},{"category":"company","date":1701777600,"headline":"Celebrating Seeking Alpha's New Analysts - November 2023 Edition","id":124305651,"image":"https://static.seekingalpha.com/uploads/2023/11/3/saupload_eHacq8EQ.png","symbol":"SWTX","publisher":"SeekingAlpha","summary":"Discover new voices and perspectives in the financial world with Seeking Alpha's November edition of their monthly series highlighting new analysts.","url":"https://seekingalpha.com/article/4655803-celebrating-seeking-alphas-new-analysts-november-2023-edition"},{"category":"company","date":1701765900,"headline":"Biggest stock movers today: CVS Health, NIO, Ericsson, Nokia and more","id":124304025,"image":"","symbol":"SWTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242231710"},{"category":"company","date":1701759240,"headline":"Biggest stock movers today: NIO, GitLab, Ericsson, Nokia and more","id":124304037,"image":"","symbol":"SWTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242103604"},{"category":"company","date":1701754980,"headline":"SpringWorks Therapeutics 9.483M share Spot Secondary priced at $29.00","id":124314321,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242036316"},{"category":"company","date":1701754320,"headline":"SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock","id":124315710,"image":"https://media.zenfs.com/en/globenewswire.com/0c953b5be9deaabd053f64d7a0ae1d9d","symbol":"SWTX","publisher":"Yahoo","summary":"STAMFORD, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the pricing of an underwritten public offering of 9,482,758 shares of its common stock at a public offering price of $29.00 per share. All of the shares in the offering are being sold by SpringWorks. The gross proceeds from the offering, before deducting underwriting discounts and commissions and","url":"https://finance.yahoo.com/news/springworks-therapeutics-announces-pricing-upsized-053200044.html"},{"category":"company","date":1701752820,"headline":"SpringWorks announces pricing of upsized public offering of common stock","id":124314322,"image":"","symbol":"SWTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242006544"},{"category":"company","date":1701749640,"headline":"Biggest stock movers today: GitLab, Ericsson, Nokia and more","id":124304057,"image":"","symbol":"SWTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241963849"},{"category":"company","date":1701724380,"headline":"SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock","id":124293592,"image":"https://media.zenfs.com/en/globenewswire.com/0c953b5be9deaabd053f64d7a0ae1d9d","symbol":"SWTX","publisher":"Yahoo","summary":"STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. All of the shares in the offering will be sold by SpringWorks. In addition, SpringWorks expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares","url":"https://finance.yahoo.com/news/springworks-therapeutics-announces-proposed-public-211300584.html"},{"category":"company","date":1701668400,"headline":"Fly Intel: After-Hours Movers","id":124293349,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241233752"},{"category":"company","date":1701660180,"headline":"SpringWorks Therapeutics $250M Spot Secondary; price range $28.80-$30.00","id":124293352,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241026138"},{"category":"company","date":1701660180,"headline":"SpringWorks Therapeutics $250M  price range $28.80-$30.00","id":124293351,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241026136"},{"category":"company","date":1701659700,"headline":"SpringWorks Therapeutics announces $250M common stock offering","id":124293354,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241015736"},{"category":"company","date":1701427643,"headline":"SpringWorks: Springing Forward On FDA Approval, Right Into Overpriced Territory","id":124225250,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/113708850/image_113708850.jpg?io=getty-c-w1536","symbol":"SWTX","publisher":"SeekingAlpha","summary":"SpringWorks Therapeutics has made a lot of waves in recent days following their first drug approval in non-cancerous desmoid tumors. Explore more details here.","url":"https://seekingalpha.com/article/4655418-springworks-stock-springing-forward-fda-approval-overpriced-territory"},{"category":"company","date":1701424620,"headline":"Biotech Alert: Searches spiking for these stocks today","id":124226086,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3237044638"},{"category":"company","date":1701412020,"headline":"Strong Buy: Springworks Therapeutics’ Ogsiveo Poised for Market Success","id":124236251,"image":"","symbol":"SWTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3236814856"},{"category":"company","date":1701346740,"headline":"Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session","id":124204725,"image":"","symbol":"SWTX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3235382648"},{"category":"company","date":1701344280,"headline":"RDHL, VIEW and PIXY among mid-day movers","id":124204108,"image":"","symbol":"SWTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3235319930"},{"category":"company","date":1701335880,"headline":"La-Z-Boy Posts Upbeat Earnings, Joins Victoria's Secret, Snowflake And Other Big Stocks Moving Higher On Thursday","id":124199397,"image":"","symbol":"SWTX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3235121542"}]}